Changes in high-density lipoprotein subfraction distribution and increased cholesteryl ester transfer after probucol

Area of Science:

• Cardiology
• Biochemistry
• Pharmacology

Background:

• Type II hypercholesterolemia is characterized by elevated cholesterol levels.
• High-density lipoprotein (HDL) plays a crucial role in reverse cholesterol transport.
• Understanding HDL subfractions and their metabolism is key to managing hypercholesterolemia.

Purpose of the Study:

• To investigate the effects of probucol on HDL subfractions.
• To assess probucol's impact on cholesteryl ester transfer from HDL.
• To evaluate probucol's influence on reverse cholesterol transport in Type II hypercholesterolemia.

Main Methods:

• Placebo-controlled crossover trial design.
• Administration of probucol (500 mg twice daily) or placebo for 8-week periods.
• Analysis of HDL subfractions using rate zonal ultracentrifugation and gradient gel electrophoresis.
• Measurement of cholesteryl ester transfer from HDL to lower density lipoproteins.

Main Results:

• Probucol significantly lowered total, LDL, and HDL cholesterol.
• A dramatic reduction in HDL2 subfractions was observed, while HDL3 remained largely unchanged.
• Probucol treatment led to a significant increase in cholesteryl ester transfer from HDL.
• Changes in HDL particle size and electrophoretic mobility indicated altered HDL composition.

Conclusions:

• Probucol significantly alters HDL subfraction composition, primarily reducing HDL2.
• The drug enhances cholesteryl ester transfer, suggesting improved reverse cholesterol transport.
• Probucol may accelerate HDL particle conversion, contributing to more efficient cholesterol clearance.